Seelos Therapeutics Inc (NASDAQ:SEEL) announced Friday it has received a Notice of Allowance from the US Patent and Trademark Office for its patent application covering SLS-007, which is being studied in Parkinson’s disease.
When a patent office examiner feels an invention qualifies for a patent, a Notice of Allowance is prepared. In the company's case, allowed claims cover composition of matter comprising at least one inhibitory peptide that inhibits the protein alpha-synuclein (α-synuclein) aggregation by binding to residues 68-78 of α-synuclein.
In a statement, Seelos said the allowed claims also cover a method of use for reducing or inhibiting α-synuclein aggregation, comprising contacting α-synuclein amyloid fibrils with an inhibitory peptide in an amount sufficient to reduce or inhibit α-synuclein aggregation plus a method of modulating the size or rate of growth of α-synuclein amyloid fibrils.
READ: Seelos Therapeutics to test Parkinson's Disease drug SLS-007 in gene therapy study
Seelos said it is currently producing adeno-associated virus viral vectors and preparing animals for pre-clinical studies.
Seelos' stock recently traded 9.5% higher to $1.00 a share in New York despite a deep market sell-off.
--UPDATES stock price--
Contact the author: patrick@proactiveinvestors.com
Follow him on Twitter @PatrickMGraham